Literature DB >> 19770792

Antibiotics for the treatment of primary sclerosing cholangitis.

Diaa Aldin H Elfaki1, Keith D Lindor.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that is associated with considerable morbidity and mortality. The disease etiopathogenesis has not been well defined. Several observations suggest that portal bacteremia or chronic bile duct infection may be factors that could play a role in the pathogenesis of the disease. Clinical trials have tested different treatments for PSC but without convincing evidence of benefit. Liver transplantation is the only available therapeutic option that is thought to be beneficial for PSC. Antibiotics have been used in several case series over the years to treat PSC and have had, in some cases, impressive benefits when compared with other drugs used for treating the disease. We gathered the available data for different antibiotics used in PSC in this review. Further studies are needed to support the efficacy of using antibiotics for PSC patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 19770792     DOI: 10.1097/MJT.0b013e3181b7b8c0

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  10 in total

1.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

Review 2.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

3.  Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.

Authors:  James H Tabibian; Andrea Gossard; Mounif El-Youssef; John E Eaton; Jan Petz; Roberta Jorgensen; Felicity B Enders; Anilga Tabibian; Keith D Lindor
Journal:  Am J Ther       Date:  2017 Jan/Feb       Impact factor: 2.688

4.  Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic.

Authors:  Masaki Shimizu; Hidenori Iwasaki; Shintaro Mase; Akihiro Yachie
Journal:  Case Rep Gastroenterol       Date:  2012-05-08

Review 5.  Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

Review 6.  Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).

Authors:  Jochen Mattner
Journal:  Int J Mol Sci       Date:  2016-11-09       Impact factor: 5.923

Review 7.  Cholangitis: Diagnosis, Treatment and Prognosis.

Authors:  Amir Houshang Mohammad Alizadeh
Journal:  J Clin Transl Hepatol       Date:  2017-09-07

8.  Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?

Authors:  Steven P O'Hara; Tom H Karlsen; Nicholas F LaRusso
Journal:  Gut       Date:  2017-07-21       Impact factor: 23.059

9.  Probiotic as a novel treatment strategy against liver disease.

Authors:  Abbas Ali Imani Fooladi; Hamideh Mahmoodzadeh Hosseini; Mohammad Reza Nourani; Soghra Khani; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-02-25       Impact factor: 0.660

Review 10.  Role of the microbiota and antibiotics in primary sclerosing cholangitis.

Authors:  James H Tabibian; Jayant A Talwalkar; Keith D Lindor
Journal:  Biomed Res Int       Date:  2013-10-22       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.